• Immunocore: Breaking new ground in immunotherapy

SCRIPAward2014

Immunocore is a privately owned, clinical-stage, UK-based biotechnology company, focused on the discovery and development of novel T cell receptor-based drugs to treat diseases with a high unmet need, including cancer and viral disease. The Company’s world-leading expertise in engineering T Cell Receptors (TCRs) and linking them to an antibody fragment (scFv) known as anti-CD3, has led to its first product candidate, IMCgp100, entering  clinical trials in patients with metastatic melanoma. The proprietary T Cell Receptor technology platform is well validated and can easily be manufactured for clinical and commercial supply in microbial systems.

Immunocore’s aim is to break new ground in immunotherapy.

Our Technology in action

ImmTAC cells

T Cell Receptors naturally recognise diseased cells. Immunocore’s competitive advantage is its ability to engineer high affinity T Cell Receptors and link them to an antibody fragment, anti-CD3, which can activate the immune system to kill the targeted cancer or viral cells. These bifunctional molecules, called ImmTACS, have the potential to be very potent anti-cancer or anti-viral agents. Watch the technology in action in a video.